Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2020 Net Income-$25.16M-$25.16MN/M vs Q3 2020 EPS Diluted-$0.73-$0.73N/M vs Q3 2020 Operating Income-$24,990,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,334,000N/M ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end